MARKET

INZY

INZY

Inozyme Pharma, Inc.
NASDAQ
7.66
+0.27
+3.65%
After Hours: 7.75 +0.09 +1.17% 19:29 03/28 EDT
OPEN
7.53
PREV CLOSE
7.39
HIGH
7.73
LOW
7.28
VOLUME
1.26M
TURNOVER
0
52 WEEK HIGH
7.73
52 WEEK LOW
2.689
MARKET CAP
473.17M
P/E (TTM)
-5.5794
1D
5D
1M
3M
1Y
5Y
Top 5 Health Care Stocks That May Plunge In March
Five stocks in the health care sector are overbought as of March 28, 2024. The RSI is a momentum indicator that compares a stock's strength on days when prices go up to its weakness. The Pennant Group, Inc. Is one of the five stocks with an RSI value of 90.
Benzinga · 1d ago
ANGI, MLKN and KOD are among after hour movers
On the Move ANGI, MLKN and KOD are among after hour movers. ATHA, XERS, KOD, PHAT, INZY, NAMSW, LENZ are among the day's losers. MillerKnoll is down 13%.
Seeking Alpha · 1d ago
Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of INZ-701 In Adults With ABCC6 Deficiency And ENPP1 Deficiency On April 8, 2024
Benzinga · 3d ago
Weekly Report: what happened at INZY last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at INZY last week (0311-0315)?
Weekly Report · 03/18 09:03
Inozyme Pharma: A Promising Buy Amid Anticipated Clinical Breakthroughs and Financial Stability
TipRanks · 03/14 09:47
Inozyme Pharma Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 03/13 13:39
Inozyme Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/13 13:39
More
About INZY
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Webull offers Inozyme Pharma Inc stock information, including NASDAQ: INZY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INZY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INZY stock methods without spending real money on the virtual paper trading platform.